rumor
    rumor
    • Screeners
    • Heatmaps
    • Charts
    • News
    • Documentation
    • Pricing
    • FAQ
    You're viewing limited data.
    Log inSign up

    Sign up

    24 hours of full access, free. No credit card.

    Log inPricing
    1 asset

    Market news

    TypeAll
    SortNewest
    Assets
    PVLA
    Type
    TypeAll
    All
    Sort
    SortNewest
    Newest

    Filter by asset

      Palvella Therapeutics to Host Webcast to Introduce New QTORIN™ Program

      Third product candidate from Palvella’s QTORIN™ platform to be announced Live audiovisual webcast to take place tomorrow, Thursday, November 19, 2026, at 8:30 a.m. ET WAYNE, Pa., Nov. 18, 2026 (GLOBE NEWSWIRE) -- Palvella Therapeutics, Inc. (Nasdaq: PVLA) (“Palvella” or the “Company”), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies for serious, rare skin diseases and vascular anomalies for which there are no U.S. Food and Drug Administration

      6h agoYahoo FinancePVLA
      Palvella Therapeutics CSO Jeffrey Martini sells $2.08M in stock
      Nov 13Investing.comPVLA
      Palvella at Stifel 2026 Healthcare Conference: launch plans take shape
      Nov 10Investing.comPVLASF
      Palvella Therapeutics Inc (PVLA) (Q3 2026) Earnings Call Highlights: FDA Priority Review, $236. ...
      Nov 5Yahoo FinancePVLA
      Palvella Therapeutics, Inc. Q3 2026 Earnings Call Summary
      Nov 5Yahoo FinancePVLA
      What Palvella Therapeutics (PVLA) Said on Its Q3 Earnings Call
      Nov 5Yahoo FinancePVLA
      Palvella Therapeutics Q3 2026 Earnings Call Transcript
      Nov 5BenzingaPVLA
      Palvella Therapeutics: Q3 Earnings Snapshot
      Nov 5Yahoo FinancePVLA
      Palvella Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update
      Nov 5Yahoo FinancePVLA
      Palvella Therapeutics stock hits 52-week high at 161.91 USD
      Nov 4Investing.comPVLA
      Palvella Therapeutics to Participate in the Stifel 2026 Healthcare Conference
      Nov 3Yahoo FinancePVLA
      Palvella Therapeutics to Host Third Quarter 2026 Financial Results and Corporate Update Conference Call on November 5, 2026
      Oct 29Yahoo FinancePVLA
      Palvella Announces FDA Acceptance and Priority Review of QTORIN™ Rapamycin NDA; February 28, 2027 PDUFA Target Action Date Set

      QTORIN™ rapamycin could become the first FDA-approved therapy for microcystic lymphatic malformations, a serious, lifelong rare disease affecting ...

      Oct 28Business InsiderPVLA
      Palvella Therapeutics Eyes QTORIN Launch as Rare-Disease Pipeline Expands
      Oct 25Yahoo FinancePVLA
      What Does Palvella Therapeutics (PVLA) NDA Progress Mean After Its Phase 3 Data?
      Oct 24Yahoo FinancePVLA
      Analysts Are Bullish on Top Healthcare Stocks: Ocular Therapeutix (OCUL), Palvella Therapeutics (PVLA)

      Detailed price information for Ocular Therapeut (OCUL-Q) from The Globe and Mail including charting and trades.

      Oct 21The Globe and MailOCULPVLA
      Palvella at Chardan conference: rare-disease push nears launch
      Oct 20Investing.comPVLA
      Palvella Therapeutics stock rating reiterated at Buy by H.C. Wainwright
      Oct 20Investing.comPVLA
      Raymond James reiterates Palvella stock Strong Buy on conference data
      Oct 16Investing.comPVLARJF
      Why is Palvella Therapeutics stock sliding 3% today?
      Oct 16Investing.comPVLA
      William Blair Initiates Coverage on Palvella Therapeutics With Outperform Rating
      Oct 16Yahoo FinancePVLA
      William Blair initiates Palvella stock with outperform rating
      Oct 16Investing.comPVLA
      Palvella to present pediatric data on rapamycin gel at PeDRA
      Oct 15Investing.comPVLA
      Palvella Therapeutics to Present Phase 3 SELVA and Phase 2 TOIVA Results, Along With New Pediatric Analyses, at 2026 PeDRA Annual Conference
      Oct 15Yahoo FinancePVLA
      Palvella Therapeutics director George M. Jenkins disposes of $3.58m PVLA stock
      Oct 14Investing.comPVLA
      Palvella Therapeutics to Participate in the Chardan 10th Annual Healthcare Conference

      WAYNE, Pa., Oct. 13, 2026 (GLOBE NEWSWIRE) -- Palvella Therapeutics, Inc. (Palvella or the “Company”) (Nasdaq: PVLA), a clinical-stage biopharma...

      Oct 13Business InsiderPVLA
      Analysts Offer Insights on Healthcare Companies: Pfizer (PFE), Palvella Therapeutics (PVLA) and Mineralys Therapeutics, Inc. (MLYS)

      Detailed price information for Pfizer Inc (PFE-N) from The Globe and Mail including charting and trades.

      Oct 13The Globe and MailMLYSPVLAPFE
      Analysts Offer Insights on Healthcare Companies: Roivant Sciences (ROIV), Bristol-Myers Squibb (BMY) and Palvella Therapeutics (PVLA)

      Detailed price information for Roivant Sciences Ltd (ROIV-Q) from The Globe and Mail including charting and trades.

      Oct 13The Globe and MailPVLAROIV
      Palvella presents data on rapamycin gel, DSAP patient analysis
      Oct 12Investing.comPVLA
      Palvella Therapeutics Announces Three Poster Presentations Highlighting New Data in Microcystic Lymphatic Malformations and DSAP at Fall Clinical Dermatology 2026
      Oct 12Yahoo FinancePVLA
      Palvella Therapeutics: FDA Handholding Makes The Regulatory Story Stronger (NASDAQ:PVLA)

      Palvella Therapeutics advances QTORIN rapamycin for microcystic lymphatic malformations with strong Phase 3 data. Read more on PVLA stock here.

      Sep 29Seeking AlphaPVLA
      Palvella Therapeutics Wins Additional US FDA Grant Funding for Rare Skin Disease Drug

      Palvella Therapeutics (PVLA) said Monday that it has received a third year of grant funding from the

      Sep 28Yahoo FinancePVLA
      Palvella receives third year of FDA grant funding for therapy
      Sep 28Investing.comPVLA
      Palvella Therapeutics director George M Jenkins sells $4.17 million in shares
      Sep 16Investing.comPVLA
      Mizuho Securities Keeps Their Buy Rating on Palvella Therapeutics (PVLA)

      Tipranks Press Release.

      Sep 11The Globe and MailPVLA
      Palvella at Cantor global healthcare conference: rare-disease push
      Sep 9Investing.comPVLA
      Palvella Therapeutics Appoints James R. Treat, M.D., Nationally Recognized Pediatric Dermatologist as Chief Medical Officer

      Brings expertise in cutaneous vascular anomalies, including microcystic lymphatic malformations, venous malformations and angiokeratomas Leader in pediatric dermatology with nearly 20 years of distinguished clinical, research, and academic experience Longstanding Palvella clinical collaborator and QTORIN™ trial investigator brings deep understanding of the unmet needs in serious, rare skin diseases including vascular anomalies Dr. Treat to lead medical strategy as Palvella moves QTORIN™ rapamyci

      Sep 9Yahoo FinancePVLA
      Palvella Therapeutics to Participate in Upcoming Healthcare Investor Conferences

      WAYNE, Pa., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Palvella Therapeutics, Inc. (Palvella or the “Company”) (Nasdaq: PVLA), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies for serious, rare skin diseases and vascular malformations for which there are no U.S. Food and Drug Administration (FDA)-approved therapies, today announced that Wes Kaupinen, Founder and Chief Executive Officer of Palvella, will participate in two upcoming healthcare investor c

      Sep 2Yahoo FinancePVLA
      Analysts Are Bullish on Top Healthcare Stocks: Palvella Therapeutics (PVLA), Protagonist Therapeutics (PTGX)

      Detailed price information for Protagonist Therapeutics Inc (PTGX-Q) from The Globe and Mail including charting and trades.

      Sep 2The Globe and MailPTGXPVLA
      Analysts Are Bullish on Top Healthcare Stocks: Palvella Therapeutics (PVLA), Protagonist Therapeutics (PTGX)

      Detailed price information for Ascendis Pharma ADR (ASND-Q) from The Globe and Mail including charting and trades.

      Sep 1The Globe and MailPTGXPVLA
      Palvella Therapeutics Completes Rolling Submission of New Drug Application to FDA for QTORIN™ Rapamycin for the Treatment of Microcystic Lymphatic Malformations
      Aug 31BarchartPVLA
      Palvella Therapeutics Completes Rolling Submission of NDA for QTORIN Rapamycin

      Palvella Therapeutics (PVLA) said Monday it has completed the rolling submission of a new drug appli

      Aug 31Yahoo FinancePVLA

      This is the newest page. Registered accounts read further back.